MLH1 and cancer: A recent study published on MedRxiv reported much lower cancer risks and families ascertained through population screening in comparison to clinical ascertainment, namely 15.2% vs. 27.1% for path_MLH1 and 3.2% vs. 25.2% for path_MSH2, respectively (25).